CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer (CALC-1)
Randomized Phase II Study of Cetuximab in Combination With Gemcitabine or Gemcitabine Followed by Cetuximab in Advanced Non Small-cell Lung Cancer Patients Who Are Not Candidates for Platinum Based Therapy.
Sponsor: National Cancer Institute, Naples
Listed as NCT00330746, this PHASE2 trial focuses on Advanced Non-Small Cell Lung Cancer and remains completed. Sponsored by National Cancer Institute, Naples, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute, Naples
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arco, Italy , Campobasso, Italy , Chieti, Italy , Fano, Italy , Frosinone, Italy , Gaeta, Italy , Genova, Italy , Mantova, Italy , Messina, Italy , Milan, Italy and 12 more locations